» Articles » PMID: 25012579

Birth Prevalence of Fatty Acid β-Oxidation Disorders in Iberia

Overview
Journal JIMD Rep
Publisher Wiley
Date 2014 Jul 12
PMID 25012579
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondrial fatty acid β-oxidation disorders (FAOD) are main targets for newborn screening (NBS) programs, which are excellent data sources for accurate estimations of disease birth prevalence. Epidemiological data is of key importance for the understanding of the natural history of the disorders as well as to define more effective public health strategies. In order to estimate FAOD birth prevalence in Iberia, the authors collected data from six NBS programs from Portugal and Spain, encompassing the screening of more than 1.6 million newborns by tandem mass spectrometry (MS/MS), and compared it with available data from other populations. The participating NBS programs are responsible for the screening of about 46% of all Iberian newborns. Data reveals that Iberia has one of the highest FAOD prevalence in Europe (1:7,914) and that Portugal has the highest birth prevalence of FAOD reported so far (1:6,351), strongly influenced by the high prevalence of medium-chain acyl-CoA dehydrogenase deficiency (MCADD; 1:8,380), one of the highest ever reported. This is justified by the fact that more than 90% of Portuguese MCADD patients are of Gypsy origin, a community characterized by a high degree of consanguinity. From the comparative analysis of various populations with comparable data other differences emerge, which points to the existence of significant variations in FAOD prevalences among different populations, but without any clear European variation pattern. Considering that FAOD are one of the justifications for MS/MS NBS, the now estimated birth prevalences stress the need to screen all Iberian newborns for this group of inherited metabolic disorders.

Citing Articles

Portuguese Neonatal Screening Program: A Cohort Study of 18 Years Using MS/MS.

Goncalves M, Marcao A, Sousa C, Nogueira C, Fonseca H, Rocha H Int J Neonatal Screen. 2024; 10(1).

PMID: 38535129 PMC: 10971468. DOI: 10.3390/ijns10010025.


Medium-chain Acyl-COA dehydrogenase deficiency: Pathogenesis, diagnosis, and treatment.

Mason E, Hindmarch C, Dunham-Snary K Endocrinol Diabetes Metab. 2022; 6(1):e385.

PMID: 36300606 PMC: 9836253. DOI: 10.1002/edm2.385.


Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?.

Mu X, Yang M, Ling P, Wu A, Zhou H, Jiang J Diabetes Metab Syndr Obes. 2022; 15:247-256.

PMID: 35125878 PMC: 8811266. DOI: 10.2147/DMSO.S350233.


Screening and follow-up results of fatty acid oxidative metabolism disorders in 608 818 newborns in Jining, Shandong province.

Yang C, Shi C, Zhou C, Wan Q, Zhou Y, Chen X Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021; 50(4):472-480.

PMID: 34704412 PMC: 8714482. DOI: 10.3724/zdxbyxb-2021-0259.


Admixture Has Shaped Romani Genetic Diversity in Clinically Relevant Variants.

Font-Porterias N, Gimenez A, Carballo-Mesa A, Calafell F, Comas D Front Genet. 2021; 12:683880.

PMID: 34220960 PMC: 8244592. DOI: 10.3389/fgene.2021.683880.


References
1.
Kasper D, Ratschmann R, Metz T, Mechtler T, Moslinger D, Konstantopoulou V . The national Austrian newborn screening program - eight years experience with mass spectrometry. past, present, and future goals. Wien Klin Wochenschr. 2010; 122(21-22):607-13. DOI: 10.1007/s00508-010-1457-3. View

2.
Al-Hassnan Z, Imtiaz F, Al-Amoudi M, Rahbeeni Z, Al-Sayed M, Al-Owain M . Medium-chain acyl-CoA dehydrogenase deficiency in Saudi Arabia: incidence, genotype, and preventive implications. J Inherit Metab Dis. 2010; 33 Suppl 3:S263-7. DOI: 10.1007/s10545-010-9143-1. View

3.
Zytkovicz T, Fitzgerald E, Marsden D, Larson C, Shih V, Johnson D . Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001; 47(11):1945-55. View

4.
Lindner M, Hoffmann G, Matern D . Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis. 2010; 33(5):521-6. DOI: 10.1007/s10545-010-9076-8. View

5.
Lund A, Hougaard D, Simonsen H, Andresen B, Christensen M, Duno M . Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening. Mol Genet Metab. 2012; 107(3):281-93. DOI: 10.1016/j.ymgme.2012.06.006. View